Research has shown that HDAC inhibitors significantly suppress intracellular lipid accumulation and alleviate hepatic steatosis, inflammation, and liver injury in mouse models of non-alcoholic steatohepatitis (55). This evidence concerns the gene HDAC9 and metabolic dysfunction-associated steatohepatitis.